Follow us on Twitter
twitter icon@FreshPatents


G Proteins patents

      

This page is updated frequently with new G Proteins-related patent applications.




 Methods for diagnosing diseases associated with human signal peptide-containing molecules patent thumbnailnew patent Methods for diagnosing diseases associated with human signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


 Antibodies comprising chimeric constant domains patent thumbnailnew patent Antibodies comprising chimeric constant domains
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
Regeneron Pharmaceuticals, Inc.


 Process for producing and purifying factor viii and its derivatives patent thumbnailnew patent Process for producing and purifying factor viii and its derivatives
Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.


 Dihydropteridinone derivatives and uses thereof patent thumbnailnew patent Dihydropteridinone derivatives and uses thereof
The present invention provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.


 Diazepane derivatives and uses thereof patent thumbnailnew patent Diazepane derivatives and uses thereof
The present invention provides compounds of any one of formulae (i), (ii-c) (e.g., formula (ii)), and (iii), and pharmaceutically compositions thereof. Compounds of any one of formulae (i), (ii-c), and (iii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.


 Compositions and methods for quantitative assessment of dna-protein complex density patent thumbnailCompositions and methods for quantitative assessment of dna-protein complex density
One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of dna binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given dna loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues.
The University Of Chicago


 Rapid protein labeling and analysis patent thumbnailRapid protein labeling and analysis
The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein.
Life Technologies Corporation


 Trispecific binding proteins and methods of use patent thumbnailTrispecific binding proteins and methods of use
Provided herein are trispecific antigen-binding proteins comprising a domain binding to cd3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins.
Harpoon Therapeutics, Inc.


 Anti-mesothelin binding proteins patent thumbnailAnti-mesothelin binding proteins
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment..
Amgen Inc.


 Human c-fms antigen binding proteins patent thumbnailHuman c-fms antigen binding proteins
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
Amgen Inc.


Immunomodulatory agents

The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc

Coronavirus proteins and antigens

Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (pedv) or porcine delta coronavirus (pdcov).
Mj Biologics, Inc.

Methods and kits for isolation and analysis of a chromatin region

The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas

Methods and products for transfecting cells

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.

Tethering cysteine residues using cyclic disulfides

Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including sod1 and dj-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker.
Brandeis University

Chimeric antigen receptor compositions

Provided herein are compositions which exhibit novel diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope).
City Of Hope

Antibodies against tl1a and uses thereof

The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
Teva Pharmaceuticals Australia Pty Ltd

Antigen binding proteins

The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid p component (sap), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, alzheimer's disease, and type 2 diabetes..
Glaxo Group Limited

Diaminopyrimidine benzenesulfone derivatives and uses thereof

The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Recombinase polymerase amplification

The present invention features novel, diverse, hybrid and engineered recombinase enzymes, and the utility of such proteins with associated recombination factors for carrying out dna amplification assays. The present invention also features different recombinase ‘systems’ having distinct biochemical activities in dna amplification assays, and differing requirements for loading factors, single-stranded dna binding proteins (ssbs), and the quantity of crowding agent employed..
Alere San Diego, Inc.

Methods and products for nucleic acid production and delivery

The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules, including cells present in vivo.
Factor Bioscience Inc.

Biosensors

The invention relates to biosensors, more particularly to protein biosensors and their use to indicate the formation of denaturing ice crystals in samples. The invention includes the use of a protein as a biosensor to indicate denaturing ice-crystal formation in a sample, wherein the protein is denaturable by denaturing ice crystals from a non-denatured state to a denatured state and wherein said non-denatured and denatured states are associated with detectably different indications, e.g.
Protein Technologies Limited

Nanopore sequencing using replicative polymerases and helicases

The present invention relates to a system of nanopore sequencing using nucleic-acid binding proteins wherein the activity of the said protein and the passage of the sequenced nucleic acid molecule through the nanopore are coordinated. In particular, the present invention enables an easy synchronization of nanopore capture with polynucleotide unwinding, which in turn affords an easy way to repeat the whole process of capture and nucleotide characterization..
Universite D'evry Val D'essonne

Dual variable domain immunoglobulins and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.

Glycoengineered binding protein compositions

Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..
Abbvie Inc.

Methods and products for transfecting cells

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.

Method for immobilizing and drying enzymes

Method for immobilizing proteins on a support, wherein the protein is incubated with the support in an aqueous phase in a discontinuous contact vacuum mixer dryer and the immobilized protein is then immediately dried, optionally following an optional washing step, in the same contact vacuum mixer dryer.. .
Basf Se

Antigen binding proteins that bind erbb3

There is disclosed compositions and methods relating to or derived from anti-erbb3 antibodies. More specifically, there is disclosed fully human antibodies that bind erbb3, erbb3-binding fragments and derivatives of such antibodies, and erbb3-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Multipartite signaling proteins and uses thereof

The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.. .
Bluebird Bio, Inc.

Synthetic genes

The invention provides synthetic nucleic acid sequences encoding proteins of interest that are particularly adapted to express well in plants. The claimed synthetic sequences utilize plant-optimized codons roughly in the same frequency at which they are utilized, on average, in genes naturally occurring in the plant species.
Dow Agrosciences Llc

Novel peptides and uses thereof

The present disclosure relates to novel peptides and their uses including, proline-rich peptides that are useful for displaying a protein of interest at the surfaces of a host cell such as a yeast. Polynucleotides, proteins, vectors and host cells that comprise or encode the novel proline-rich peptides, including libraries comprising such polynucleotides, proteins, vectors and/or host cells that comprise or encode novel proline-rich peptides are provided.
Avantgen, Inc.

Cas variants for gene editing

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided.
President And Fellows Of Harvard College

Fc receptor binding proteins

The disclosure relates to antibodies that bind fcrn and methods of using these antibodies.. .
Dyax Corporation

Peptide based inhibition of capcna interaction in cancer

Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (capcna, also known as cspcna) or from nmpcna-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods..

Circular extractor

The present invention provides methods and systems for eluting and an analyte from a solid phase. The invention further provides methods and systems for transferring liquid analyte reagent mixtures from a solid phase to a second vessel, such as a microtitre plate well.
Ge Healthcare Bio-sciences Ab

Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

The present disclosure provides modified human herpesvirus glycoprotein b (gb) proteins that incorporate unique mechanisms for generating proteins that mimic their native conformation to enhance their immunogenicity. The modified herpesvirus gb proteins insert a peptide linker at the furin cleavage site in the extracellular domain of herpesvirus gb.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Cross-linked peg polymer coating for improving biocompatibility of medical devices

The present invention relates to a cross-linked peg polymer coating that is hydrophilic, lubricious, and resistant to adsorption of biological matters including proteins and cells. The coating is created using plasma glow discharge polymerization of organic compounds with a formula r(och2ch2)noh, where r is an alkane group with 1-4 carbon atoms and n=1-6..
Medical Surface Inc

Protein-containing emulsions and adhesives, and manufacture and use thereof

This invention provides emulsions and adhesives comprising proteins that can be isolated from a variety of sources including renewable plant biomass, and methods of making and using such emulsions and adhesives.. .
Biopolymer Technologies, Ltd.

Adeno-associated virus with site-directed mutagenesis and site-directed modification and preparation method and application thereof

The present invention relates to an adeno-associated virus with site-directed mutagenesis and site-specific modification, and a preparation method and uses thereof. Specifically, the present invention uses genetic code expansion techniques to incorporate non-natural amino acid into an adeno-associated virus capsid protein vp1 or fragment thereof, thereby obtaining an adeno-associated virus with site-directed mutagenesis using the non-natural amino acid.
Peking University

High-cell density fed-batch fermentation process for producing recombinant protein

Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and optionally continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions and compositions for use in the methods of the present invention, are provided.. .
Wyeth Llc

Biosynthesis of 1-undecene and related terminal olefins

The present disclosure relates to the biosynthesis of 1-undecene and related terminal olefins. Specifically, the present disclosure relates to methods of using proteins to produce 1-undecene and related terminal olefins..
The Regents Of The University Of California

Fabs-in-tandem immunoglobulin and uses thereof

The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo..
Epimab Biotherapeutics Inc.

Fabs-in-tandem immunoglobulin and uses thereof

The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo..
Epimab Biotherapeutics Inc.

Antigen binding proteins that bind ccr2

There is disclosed compositions and methods relating to or derived from anti-ccr2 antibodies. More specifically, there is disclosed fully human antibodies that bind ccr2, ccr2-binding fragments and derivatives of such antibodies, and ccr2-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Recombinant proteins that simultaneously bind hgf, vegf-a and serum albumin, comprising ankyrin repeat domains

New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (hgf), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (vegf-a), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.. .
Molecular Partners Ag

Artificial dna-binding proteins and uses thereof

The present invention relates to proteins consisting of an artificial dna-binding domain (dbd) and related molecules and uses thereof. In particular, the proteins are zf-dbd or tale-dbd and are used for the treatment of eye disorders caused by gain of function mutation.
Fondazione Telethon

Removal of residual cell culture impurities

The present application discloses methods for removing residual impurities from protein preparations. Such methods include addition of an anionic detergent to a solution comprising proteins of interest and cellular contaminants under non-precipitating conditions and passing the solution through an ion exchange column..
Novartis Ag

Active compounds combination containing fluopyram bacillus and biologically control agent

The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (a) fluopyram, (b) a spore-forming bacterium of the genera bacillus, selected from bacillus firmus, bacillus cereus, bacillus pumilis, bacillus amyloliquefaciens, bacillus subtilis strain gb03, bacillus subtilis strain qst713, and (c) at least one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites. Moreover, the invention relates to a method for curatively or preventively controlling insects, nematodes or phytopathogens on the plant, plant parts, harvested fruits or vegetables, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed..
Bayer Cropscience Ag

Lipid probes and uses thereof

Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands..

Determination of the unbound free fatty acid profiles in biological and industrial specimens

The invention relates to determination of the profile of unbound free fatty acids (ffau) in biological samples, such as human and animal blood specimens and plant and animal oils, by measuring the fluorescence response of sets of different fluorescently labeled fatty acid binding proteins (probes) that undergo a change in fluorescence ratio at 2 wavelengths upon binding an ffau. Use of these profiles in human and animal disease, in basic research, in drug development and in industrial uses is disclosed..



G Proteins topics:
  • G Proteins
  • Antibodies
  • Immunoglobulin
  • Metalloprotein
  • Chemotherapeutic Agent
  • Kinase Inhibitor
  • Tetrapeptide
  • Apoptosis Protein
  • Topoisomerase
  • Peptidomimetic
  • Fractionation
  • Medical Treatment
  • Chromatograph
  • Encapsulation
  • Electrospraying


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9582

    file did exist - 2353

    2 - 1 - 51